9 results on '"Eicher, Jean Christophe"'
Number of results to display per page
Search Results
2. Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction
- Author
-
Girerd, Nicolas, Von Hunolstein, Jean-Jacques, Pellicori, Pierpaolo, Bayes-Genis, Antoni, Jaarsma, Tiny, Lund, Lars H., Bilbault, Pascal, Boivin, Jean-Marc, Chouihed, Tahar, Costa, Jerome, Eicher, Jean-Christophe, Fall, Estelle, Kenizou, David, Maillier, Bruno, Nazeyrollas, Pierre, Roul, Gerald, Zannad, Noura, Rossignol, Patrick, Seronde, Marie-France, Girerd, Nicolas, Von Hunolstein, Jean-Jacques, Pellicori, Pierpaolo, Bayes-Genis, Antoni, Jaarsma, Tiny, Lund, Lars H., Bilbault, Pascal, Boivin, Jean-Marc, Chouihed, Tahar, Costa, Jerome, Eicher, Jean-Christophe, Fall, Estelle, Kenizou, David, Maillier, Bruno, Nazeyrollas, Pierre, Roul, Gerald, Zannad, Noura, Rossignol, Patrick, and Seronde, Marie-France
- Published
- 2022
- Full Text
- View/download PDF
3. Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure
- Author
-
Borlaug, Barry A., Blair, John, Bergmann, Martin W., Bugger, Heiko, Burkhoff, Dan, Bruch, Leonhard, Celermajer, David S., Claggett, Brian, Cleland, John G.F., Cutlip, Donald E., Dauber, Ira, Eicher, Jean Christophe, Gao, Qi, Gorter, Thomas M., Gustafsson, Finn, Hayward, Chris, Van Der Heyden, Jan, Hasenfuß, Gerd, Hummel, Scott L., Kaye, David M., Komtebedde, Jan, Massaro, Joseph M., Mazurek, Jeremy A., McKenzie, Scott, Mehta, Shamir R., Petrie, Mark C., Post, Marco C., Nair, Ajith, Rieth, Andreas, Silvestry, Frank E., Solomon, Scott D., Trochu, Jean Noël, Van Veldhuisen, Dirk J., Westenfeld, Ralf, Leon, Martin B., Shah, Sanjiv J., Borlaug, Barry A., Blair, John, Bergmann, Martin W., Bugger, Heiko, Burkhoff, Dan, Bruch, Leonhard, Celermajer, David S., Claggett, Brian, Cleland, John G.F., Cutlip, Donald E., Dauber, Ira, Eicher, Jean Christophe, Gao, Qi, Gorter, Thomas M., Gustafsson, Finn, Hayward, Chris, Van Der Heyden, Jan, Hasenfuß, Gerd, Hummel, Scott L., Kaye, David M., Komtebedde, Jan, Massaro, Joseph M., Mazurek, Jeremy A., McKenzie, Scott, Mehta, Shamir R., Petrie, Mark C., Post, Marco C., Nair, Ajith, Rieth, Andreas, Silvestry, Frank E., Solomon, Scott D., Trochu, Jean Noël, Van Veldhuisen, Dirk J., Westenfeld, Ralf, Leon, Martin B., and Shah, Sanjiv J.
- Abstract
Background: In REDUCE LAP-HF II (A Study to Evaluate the Corvia Medical, Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure), implantation of an atrial shunt device did not provide overall clinical benefit for patients with heart failure with preserved or mildly reduced ejection fraction. However, prespecified analyses identified differences in response in subgroups defined by pulmonary artery systolic pressure during submaximal exercise, right atrial volume, and sex. Shunt implantation reduces left atrial pressures but increases pulmonary blood flow, which may be poorly tolerated in patients with pulmonary vascular disease (PVD). On the basis of these results, we hypothesized that patients with latent PVD, defined as elevated pulmonary vascular resistance during exercise, might be harmed by shunt implantation, and conversely that patients without PVD might benefit. Methods: REDUCE LAP-HF II enrolled 626 patients with heart failure, ejection fraction ≥40%, exercise pulmonary capillary wedge pressure ≥25 mm Hg, and resting pulmonary vascular resistance <3.5 Wood units who were randomized 1:1 to atrial shunt device or sham control. The primary outcome - a hierarchical composite of cardiovascular death, nonfatal ischemic stroke, recurrent HF events, and change in health status - was analyzed using the win ratio. Latent PVD was defined as pulmonary vascular resistance ≥1.74 Wood units (highest tertile) at peak exercise, measured before randomization. Results: Compared with patients without PVD (n=382), those with latent PVD (n=188) were older, had more atrial fibrillation and right heart dysfunction, and were more likely to have elevated left atrial pressure at rest. Shunt treatment was associated with worse outcomes in patients with PVD (win ratio, 0.60 [95% CI, 0.42, 0.86]; P=0.005) and signal of clinical benefit in patients without PVD (win ratio, 1.31 [95% CI, 1.02, 1.68]; P=0.038). Patients with larger right atrial volum
- Published
- 2022
4. Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction
- Author
-
Girerd, Nicolas, Von Hunolstein, Jean-Jacques, Pellicori, Pierpaolo, Bayes-Genis, Antoni, Jaarsma, Tiny, Lund, Lars H., Bilbault, Pascal, Boivin, Jean-Marc, Chouihed, Tahar, Costa, Jerome, Eicher, Jean-Christophe, Fall, Estelle, Kenizou, David, Maillier, Bruno, Nazeyrollas, Pierre, Roul, Gerald, Zannad, Noura, Rossignol, Patrick, Seronde, Marie-France, Girerd, Nicolas, Von Hunolstein, Jean-Jacques, Pellicori, Pierpaolo, Bayes-Genis, Antoni, Jaarsma, Tiny, Lund, Lars H., Bilbault, Pascal, Boivin, Jean-Marc, Chouihed, Tahar, Costa, Jerome, Eicher, Jean-Christophe, Fall, Estelle, Kenizou, David, Maillier, Bruno, Nazeyrollas, Pierre, Roul, Gerald, Zannad, Noura, Rossignol, Patrick, and Seronde, Marie-France
- Published
- 2022
- Full Text
- View/download PDF
5. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II):a randomised, multicentre, blinded, sham-controlled trial
- Author
-
Shah, Sanjiv J., Borlaug, Barry A., Chung, Eugene, Cutlip, Donald E., Debonnaire, Philippe, Fail, Peter, Gao, Qi, Hasenfuß, Gerd, Kahwash, Rami, Kaye, David M., Litwin, Sheldon E., Lurz, Philipp, Massaro, Joseph M., Mohan, Rajeev C., Ricciardi, Mark J., Solomon, Scott D., Sverdlov, Aaron L., Swarup, Vijendra, van Veldhuisen, Dirk J., Winkler, Sebastian, Leon, Martin B., Akar, Joseph, Ando, Jiro, Anzai, Toshihisa, Asakura, Masanori, Bailey, Steven, Basuray, Anupam, Bauer, Fabrice, Bergmann, Martin, Blair, John, Cavendish, Jeffrey, Cikes, Maja, Dauber, Ira, Donal, Erwan, Eicher, Jean Christophe, Flaherty, James, Freixa, Xavier, Gafoor, Sameer, Gertz, Zachary, Gordon, Robert, Guazzi, Marco, Guerrero-Miranda, Cesar, Gupta, Deepak, Gustafsson, Finn, Hadadi, Cyrus, Hakemi, Emad, Handoko, Louis, Hass, Moritz, Shah, Sanjiv J., Borlaug, Barry A., Chung, Eugene, Cutlip, Donald E., Debonnaire, Philippe, Fail, Peter, Gao, Qi, Hasenfuß, Gerd, Kahwash, Rami, Kaye, David M., Litwin, Sheldon E., Lurz, Philipp, Massaro, Joseph M., Mohan, Rajeev C., Ricciardi, Mark J., Solomon, Scott D., Sverdlov, Aaron L., Swarup, Vijendra, van Veldhuisen, Dirk J., Winkler, Sebastian, Leon, Martin B., Akar, Joseph, Ando, Jiro, Anzai, Toshihisa, Asakura, Masanori, Bailey, Steven, Basuray, Anupam, Bauer, Fabrice, Bergmann, Martin, Blair, John, Cavendish, Jeffrey, Cikes, Maja, Dauber, Ira, Donal, Erwan, Eicher, Jean Christophe, Flaherty, James, Freixa, Xavier, Gafoor, Sameer, Gertz, Zachary, Gordon, Robert, Guazzi, Marco, Guerrero-Miranda, Cesar, Gupta, Deepak, Gustafsson, Finn, Hadadi, Cyrus, Hakemi, Emad, Handoko, Louis, and Hass, Moritz
- Abstract
Background: Placement of an interatrial shunt device reduces pulmonary capillary wedge pressure during exercise in patients with heart failure and preserved or mildly reduced ejection fraction. We aimed to investigate whether an interatrial shunt can reduce heart failure events or improve health status in these patients. Methods: In this randomised, international, blinded, sham-controlled trial performed at 89 health-care centres, we included patients (aged ≥40 years) with symptomatic heart failure, an ejection fraction of at least 40%, and pulmonary capillary wedge pressure during exercise of at least 25 mm Hg while exceeding right atrial pressure by at least 5 mm Hg. Patients were randomly assigned (1:1) to receive either a shunt device or sham procedure. Patients and outcome assessors were masked to randomisation. The primary endpoint was a hierarchical composite of cardiovascular death or non-fatal ischemic stroke at 12 months, rate of total heart failure events up to 24 months, and change in Kansas City Cardiomyopathy Questionnaire overall summary score at 12 months. Pre-specified subgroup analyses were conducted for the heart failure event endpoint. Analysis of the primary endpoint, all other efficacy endpoints, and safety endpoints was conducted in the modified intention-to-treat population, defined as all patients randomly allocated to receive treatment, excluding those found to be ineligible after randomisation and therefore not treated. This study is registered with ClinicalTrials.gov, NCT03088033. Findings: Between May 25, 2017, and July 24, 2020, 1072 participants were enrolled, of whom 626 were randomly assigned to either the atrial shunt device (n=314) or sham procedure (n=312). There were no differences between groups in the primary composite endpoint (win ratio 1·0 [95% CI 0·8–1·2]; p=0·85) or in the individual components of the primary endpoint. The prespecified subgroups demonstrating a differential effect of atrial shunt device treatment on hea
- Published
- 2022
6. Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure
- Author
-
Borlaug, Barry A., Blair, John, Bergmann, Martin W., Bugger, Heiko, Burkhoff, Dan, Bruch, Leonhard, Celermajer, David S., Claggett, Brian, Cleland, John G.F., Cutlip, Donald E., Dauber, Ira, Eicher, Jean Christophe, Gao, Qi, Gorter, Thomas M., Gustafsson, Finn, Hayward, Chris, Van Der Heyden, Jan, Hasenfuß, Gerd, Hummel, Scott L., Kaye, David M., Komtebedde, Jan, Massaro, Joseph M., Mazurek, Jeremy A., McKenzie, Scott, Mehta, Shamir R., Petrie, Mark C., Post, Marco C., Nair, Ajith, Rieth, Andreas, Silvestry, Frank E., Solomon, Scott D., Trochu, Jean Noël, Van Veldhuisen, Dirk J., Westenfeld, Ralf, Leon, Martin B., Shah, Sanjiv J., Borlaug, Barry A., Blair, John, Bergmann, Martin W., Bugger, Heiko, Burkhoff, Dan, Bruch, Leonhard, Celermajer, David S., Claggett, Brian, Cleland, John G.F., Cutlip, Donald E., Dauber, Ira, Eicher, Jean Christophe, Gao, Qi, Gorter, Thomas M., Gustafsson, Finn, Hayward, Chris, Van Der Heyden, Jan, Hasenfuß, Gerd, Hummel, Scott L., Kaye, David M., Komtebedde, Jan, Massaro, Joseph M., Mazurek, Jeremy A., McKenzie, Scott, Mehta, Shamir R., Petrie, Mark C., Post, Marco C., Nair, Ajith, Rieth, Andreas, Silvestry, Frank E., Solomon, Scott D., Trochu, Jean Noël, Van Veldhuisen, Dirk J., Westenfeld, Ralf, Leon, Martin B., and Shah, Sanjiv J.
- Abstract
Background: In REDUCE LAP-HF II (A Study to Evaluate the Corvia Medical, Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure), implantation of an atrial shunt device did not provide overall clinical benefit for patients with heart failure with preserved or mildly reduced ejection fraction. However, prespecified analyses identified differences in response in subgroups defined by pulmonary artery systolic pressure during submaximal exercise, right atrial volume, and sex. Shunt implantation reduces left atrial pressures but increases pulmonary blood flow, which may be poorly tolerated in patients with pulmonary vascular disease (PVD). On the basis of these results, we hypothesized that patients with latent PVD, defined as elevated pulmonary vascular resistance during exercise, might be harmed by shunt implantation, and conversely that patients without PVD might benefit. Methods: REDUCE LAP-HF II enrolled 626 patients with heart failure, ejection fraction ≥40%, exercise pulmonary capillary wedge pressure ≥25 mm Hg, and resting pulmonary vascular resistance <3.5 Wood units who were randomized 1:1 to atrial shunt device or sham control. The primary outcome - a hierarchical composite of cardiovascular death, nonfatal ischemic stroke, recurrent HF events, and change in health status - was analyzed using the win ratio. Latent PVD was defined as pulmonary vascular resistance ≥1.74 Wood units (highest tertile) at peak exercise, measured before randomization. Results: Compared with patients without PVD (n=382), those with latent PVD (n=188) were older, had more atrial fibrillation and right heart dysfunction, and were more likely to have elevated left atrial pressure at rest. Shunt treatment was associated with worse outcomes in patients with PVD (win ratio, 0.60 [95% CI, 0.42, 0.86]; P=0.005) and signal of clinical benefit in patients without PVD (win ratio, 1.31 [95% CI, 1.02, 1.68]; P=0.038). Patients with larger right atrial volum
- Published
- 2022
7. Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction
- Author
-
Girerd, Nicolas, Von Hunolstein, Jean-Jacques, Pellicori, Pierpaolo, Bayes-Genis, Antoni, Jaarsma, Tiny, Lund, Lars H., Bilbault, Pascal, Boivin, Jean-Marc, Chouihed, Tahar, Costa, Jerome, Eicher, Jean-Christophe, Fall, Estelle, Kenizou, David, Maillier, Bruno, Nazeyrollas, Pierre, Roul, Gerald, Zannad, Noura, Rossignol, Patrick, Seronde, Marie-France, Girerd, Nicolas, Von Hunolstein, Jean-Jacques, Pellicori, Pierpaolo, Bayes-Genis, Antoni, Jaarsma, Tiny, Lund, Lars H., Bilbault, Pascal, Boivin, Jean-Marc, Chouihed, Tahar, Costa, Jerome, Eicher, Jean-Christophe, Fall, Estelle, Kenizou, David, Maillier, Bruno, Nazeyrollas, Pierre, Roul, Gerald, Zannad, Noura, Rossignol, Patrick, and Seronde, Marie-France
- Published
- 2022
- Full Text
- View/download PDF
8. Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction
- Author
-
Girerd, Nicolas, Von Hunolstein, Jean-Jacques, Pellicori, Pierpaolo, Bayes-Genis, Antoni, Jaarsma, Tiny, Lund, Lars H., Bilbault, Pascal, Boivin, Jean-Marc, Chouihed, Tahar, Costa, Jerome, Eicher, Jean-Christophe, Fall, Estelle, Kenizou, David, Maillier, Bruno, Nazeyrollas, Pierre, Roul, Gerald, Zannad, Noura, Rossignol, Patrick, Seronde, Marie-France, Girerd, Nicolas, Von Hunolstein, Jean-Jacques, Pellicori, Pierpaolo, Bayes-Genis, Antoni, Jaarsma, Tiny, Lund, Lars H., Bilbault, Pascal, Boivin, Jean-Marc, Chouihed, Tahar, Costa, Jerome, Eicher, Jean-Christophe, Fall, Estelle, Kenizou, David, Maillier, Bruno, Nazeyrollas, Pierre, Roul, Gerald, Zannad, Noura, Rossignol, Patrick, and Seronde, Marie-France
- Published
- 2022
- Full Text
- View/download PDF
9. Sex‐ and Age‐Related Differences in the Management and Outcomes of Chronic Heart Failure: an Analysis of Patients from the ESC HFA EORP Heart Failure Long‐Term Registry
- Author
-
Lainscak, Mitja, Milinković, Ivan, Polovina, Marija, Crespo-Leiro, María Generosa, Lund, Lars H., Anker, Stefan, Laroche, Cécile, Ferrari, Roberto, Coats, Andrew J.S., McDonagh, Theresa A., Filippatos, Gerasimos, Maggioni, Aldo P., Piepoli, Massimo Francesco, Rosano, Giuseppe, Ruschitzka, Frank, Simić, Dragan, Ašanin, Milika, Eicher, Jean‐Christophe, Yilmaz, Mehmet Birhan, Seferovic, Petar M., Lainscak, Mitja, Milinković, Ivan, Polovina, Marija, Crespo-Leiro, María Generosa, Lund, Lars H., Anker, Stefan, Laroche, Cécile, Ferrari, Roberto, Coats, Andrew J.S., McDonagh, Theresa A., Filippatos, Gerasimos, Maggioni, Aldo P., Piepoli, Massimo Francesco, Rosano, Giuseppe, Ruschitzka, Frank, Simić, Dragan, Ašanin, Milika, Eicher, Jean‐Christophe, Yilmaz, Mehmet Birhan, and Seferovic, Petar M.
- Abstract
[Abstract] Aims. This study aimed to assess age‐ and sex‐related differences in management and 1‐year risk for all‐cause mortality and hospitalization in chronic heart failure (HF) patients. Methods and results. Of 16 354 patients included in the European Society of Cardiology Heart Failure Long‐Term Registry, 9428 chronic HF patients were analysed [median age: 66 years; 28.5% women; mean left ventricular ejection fraction (LVEF) 37%]. Rates of use of guideline‐directed medical therapy (GDMT) were high (angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, beta‐blockers and mineralocorticoid receptor antagonists: 85.7%, 88.7% and 58.8%, respectively). Crude GDMT utilization rates were lower in women than in men (all differences: P ≤ 0.001), and GDMT use became lower with ageing in both sexes, at baseline and at 1‐year follow‐up. Sex was not an independent predictor of GDMT prescription; however, age >75 years was a significant predictor of GDMT underutilization. Rates of all‐cause mortality were lower in women than in men (7.1% vs. 8.7%; P = 0.015), as were rates of all‐cause hospitalization (21.9% vs. 27.3%; P < 0.001) and there were no differences in causes of death. All‐cause mortality and all‐cause hospitalization increased with greater age in both sexes. Sex was not an independent predictor of 1‐year all‐cause mortality (restricted to patients with LVEF ≤45%). Mortality risk was significantly lower in patients of younger age, compared to patients aged >75 years. Conclusions. There was a decline in GDMT use with advanced age in both sexes. Sex was not an independent predictor of GDMT or adverse outcomes. However, age >75 years independently predicted lower GDMT use and higher all‐cause mortality in patients with LVEF ≤45%.
- Published
- 2019
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.